Outcome after treatment for sebaceous carcinoma: A multicenter study

Eva Huis In 't Veld, Ronald de Keizer, Nicoline Post, Jeroen Versteeg, Robert Verdijk, Nicole Naus, Germaine Relyveld, Marianne Crijns, Myles Smith, Dirk Grünhagen, Marlies Wakkee, Dion Paridaens, Ioannis Zavrakidis, Antien Mooyaart, Alexander van Akkooi, Dirk Strauss, Cornelis Verhoef, Michel Wouters, Andrew Hayes, Winan van Houdt

Research output: Contribution to journalArticleResearchpeer-review


BACKGROUND: Sebaceous carcinoma (SC) is a rare malignant tumour whereby, comprehensive long-term data are scarce. This study aimed to assess the outcome of patients treated with resection for SC.

METHODS: Patients treated at four tertiary centres were included. Cumulative incidence curves were calculated for recurrences.

RESULTS: A total of 100 patients (57 males, 57%) were included with 103 SCs. The median age was 72 (range, 15-95) years with a median follow-up of 52 (interquartile range [IQR], 24-93) months. Most SCs were located (peri)ocular (49.5%). Of all SCs, 17 locally recurred (16.5%) with a median time to recurrence of 19 (IQR, 8-29) months. The cumulative incidence probability for recurrence was statistically higher for (peri)ocular tumours (p = 0.005), and for positive resection margins (p = 0.001). Two patients presented with lymph node metastases and additional seven patients (8.7%) developed lymph node metastases during follow-up with a median time to metastases of 8 (IQR, 0.5-28) months. Three patients had concurrent in-transit metastases and one patient also developed liver and bone metastases during follow-up.

CONCLUSION: SC is a rare, yet locally aggressive tumour. Positive resection margins and (peri)ocular SCs are more frequently associated with local recurrence. SC infrequently presents with locoregional or distant metastases.

Original languageEnglish
Pages (from-to)730-735
Number of pages6
JournalJournal of Surgical Oncology
Issue number4
Publication statusPublished - Mar 2022


Dive into the research topics of 'Outcome after treatment for sebaceous carcinoma: A multicenter study'. Together they form a unique fingerprint.

Cite this